Feature Data Briefing

Crossing the line: NICE’s value for money threshold

BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1336 (Published 09 March 2016) Cite this as: BMJ 2016;352:i1336
  1. John Appleby, chief economist
  1. King’s Fund, London, UK
  1. j.appleby{at}kingsfund.org.uk

John Appleby explains the link between the NICE threshold and the NHS budget and considers whether it is right

For a publicly funded health service, deciding what services and treatments should be available to patients is not just a matter of getting the best value for every (scarce) pound spent but an ethical duty too. Choosing “what’s in and what’s out” quite literally involves decisions about life and death; the cost of getting a decision wrong can be measured not just in wasted resources but in avoidable deaths and lower quality of life. In this respect, the creation of the National Institute for Health and Clinical Excellence (NICE) 17 years ago was a watershed moment. For the first time there was an organisation required to advise the NHS explicitly on what it should offer to patients, drawing on evidence of the clinical benefits and the cost of obtaining those benefits.

But NICE—and the growing number of sister organisations in other countries—faced a problem from the outset. At what point …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe